Attendee search 

Sorrento Therapeutics, Inc. is a development-stage biopharmaceutical company focused on applying its proprietary technology platform for the discovery and development of human therapeutic antibodies for the treatment of a variety of disease conditions, including cancer, inflammation, metabolic disease and infectious disease. The Company has constructed antibody libraries containing fully human antibodies and designed to facilitate the rapid identification and isolation of highly specific, antibody therapeutic product candidates that are fully human and that bind to disease targets.

The Ono Pharmaceutical Group, in keeping with our philosophy of "Dedicated to Man's Fight against Disease and Pain," has always striven to serve as an R&D-oriented international pharmaceutical company.  In this endeavor we have placed our emphasis on creating innovative medicines that meet international requirements.  In addition to its own original research and development efforts, Ono has been very activly seeking a in-licensing opportunity from companies inside and outside Japan.

Kowa Company, Ltd is a privately-held Japanese corporation headquartered in Nagoya. Since its establishment as a textile wholesaler in 1894, Kowa has grown into a multinational company with 48 affiliates around the world and has built a strong position in developing, manufacturing, marketing and trading products within a variety of businesses. Kowa started its pharmaceutical business in 1947, and has since built a strong presence in the Japanese prescription and OTC drug markets and it is growing rapidly overseas.

Areas of Interest

•      Cardiovascular

•      Metabolic Syndromes

•      Pain Management

•      Auto-inflammatory

•      Gastroenterological

Partnership Structures

•      Co-development

•      Co-commercialization

•      Licensing

•      Across all stages of development & commercialization

Kimberly-Clark has developed an innovative transdermal drug delivery technology for Biologics.  The Biologic Transdermal System is designed to deliver large molecular weight biologics (demonstrated up to 150,000 Daltons) without a pump or other secondary device.   Kimberly-Clark has a rich heritage of providing innovative, high quality products for both consumer and B2B markets, including its $1.5 billion healthcare division that manufactures and markets a broad range of medical devices and medical supplies.

Depomed, Inc. (Nasdaq:  DEPO) is a US based specialty pharmaceutical company with a focus in pain, CNS, and Women's Health.  The company has advanced three products to market and has developed a pipeline with late-stage product opportunities intended to address common medical conditions affecting large patient populations

Depomed is currently seeking US co-promotion, and Global license partners for it's marketed product Gralise (once-daily gabapentin for Post Herpetic Neuralgia), and Serada a non-hormonal treatment for Vasomotor Symptoms (menopausal hot flashes) which is currently under in registration.

Dicerna Technology: Next Generation RNAi and RNAi Delivery

Dicerna is a leading developer of RNAi drugs targeting unmet needs in cancer. The company’s novel Dicer Substrate siRNA (DsiRNA) molecules and proprietary drug delivery technologies have the demonstrated ability to silence previously undruggable disease targets. Dicerna’s RNAi platform is comprised of two key components: Dicer Substrates (DsiRNAs), which are 25-30 asymmetric double stranded RNAs that mediate RNAi with extremely high potency, and EnCore lipid nanoparticles, which are optimized for tumor delivery of RNAi molecules. The DsiRNA platform is broadly covered by the recently issued US patent 8,084,599.

Dicerna DsiRNA and Delivery Technologies enable breakthrough cancer treatments based on previously undruggable targets

Robust in vivo anti-tumor efficacy has been achieved in multiple difficult-to-treat tumors using DsiRNA Technology against classic undruggable oncology targets, both within our own pipeline and with our partner Kyowa Kirin. The company’s most advanced program targets the MYC oncogene and is focused on Hepatocellular Carcinoma (HCC), where there still remains a significant need for new treatment options. The HCC program is available for partnering.

Recent accomplishments

·         The demonstration of profound tumor responses in multiple solid tumor xenograft models.

·         The recent announcements that our partner, Kyowa Kirin, has moved the initial oncology candidate into formal development, triggering a substantial success milestone and the achievement of the in vivo efficacy milestone for the second DsiRNA oncology candidate.

·         The characterization and optimization of our EnCore lipid nanoparticle (LNP) technology and its ability to deliver DsiRNA payloads into the cell cytoplasm and achieve efficient knockdown of targeted genes.

·         The issuance of the fundamental patent covering the DsiRNA platform.

At Dicerna we can rapidly generate DsiRNA inhibitors against any gene and optimize our EnCore delivery technology to deliver to specific tumor types or organs.  We have demonstrated these capabilities in our lead HCC program, available for partnering, and can use these capabilities to develop therapeutics against targets of interest to collaborators.  I hope you have the time to meet with Dicerna during BioNetwork West to discuss our technology and areas of possible mutual interest.